Psychiatric Applications of Viral Vectors

Thomas Green, Eric J. Nestler

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

This chapter compares and contrasts four viral vector systems (herpes simplex 1 virus, adeno-associated virus, sindbis virus, and lentivirus), best suited for gene transfer into the brain and describes the basic strategies where viral-mediated gene transfer has proven useful. The ideal viral vector for psychiatric research in animals, and eventually for treatments of humans, must have good neurotropism, cause little or no toxicity, and express the target protein(s) for extended periods of time. Viral vectors expressing the transcription factor, cAMP-response-element binding protein (CREB) or a dominant-negative mutant form of CREB (mCREB) affect behavior in rodent models ranging from depression to anxiety to drug dependence. The final discussion outlines novel uses and improvements to vector technology and describes current obstacles preventing viral vectors from becoming clinically viable. Obstacles to a clinically viable gene therapy include finding good targets, designing better vectors, controlling expression, and safety issues.

Original languageEnglish (US)
Title of host publicationGene Therapy of the Central Nervous System: From Bench to Bedside
PublisherElsevier Inc.
Pages181-193
Number of pages13
ISBN (Print)9780123976321
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Cyclic AMP Response Element-Binding Protein
Psychiatry
Sindbis Virus
Dependovirus
Lentivirus
Viral Genes
Human Herpesvirus 1
Viruses
Genetic Therapy
Substance-Related Disorders
Gene transfer
Rodentia
Transcription Factors
Anxiety
Depression
Technology
Safety
Brain
Genes
Gene therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Green, T., & Nestler, E. J. (2006). Psychiatric Applications of Viral Vectors. In Gene Therapy of the Central Nervous System: From Bench to Bedside (pp. 181-193). Elsevier Inc.. https://doi.org/10.1016/B978-012397632-1/50015-0

Psychiatric Applications of Viral Vectors. / Green, Thomas; Nestler, Eric J.

Gene Therapy of the Central Nervous System: From Bench to Bedside. Elsevier Inc., 2006. p. 181-193.

Research output: Chapter in Book/Report/Conference proceedingChapter

Green, T & Nestler, EJ 2006, Psychiatric Applications of Viral Vectors. in Gene Therapy of the Central Nervous System: From Bench to Bedside. Elsevier Inc., pp. 181-193. https://doi.org/10.1016/B978-012397632-1/50015-0
Green T, Nestler EJ. Psychiatric Applications of Viral Vectors. In Gene Therapy of the Central Nervous System: From Bench to Bedside. Elsevier Inc. 2006. p. 181-193 https://doi.org/10.1016/B978-012397632-1/50015-0
Green, Thomas ; Nestler, Eric J. / Psychiatric Applications of Viral Vectors. Gene Therapy of the Central Nervous System: From Bench to Bedside. Elsevier Inc., 2006. pp. 181-193
@inbook{375c87c39a2c47dbad2a3fce581e15f9,
title = "Psychiatric Applications of Viral Vectors",
abstract = "This chapter compares and contrasts four viral vector systems (herpes simplex 1 virus, adeno-associated virus, sindbis virus, and lentivirus), best suited for gene transfer into the brain and describes the basic strategies where viral-mediated gene transfer has proven useful. The ideal viral vector for psychiatric research in animals, and eventually for treatments of humans, must have good neurotropism, cause little or no toxicity, and express the target protein(s) for extended periods of time. Viral vectors expressing the transcription factor, cAMP-response-element binding protein (CREB) or a dominant-negative mutant form of CREB (mCREB) affect behavior in rodent models ranging from depression to anxiety to drug dependence. The final discussion outlines novel uses and improvements to vector technology and describes current obstacles preventing viral vectors from becoming clinically viable. Obstacles to a clinically viable gene therapy include finding good targets, designing better vectors, controlling expression, and safety issues.",
author = "Thomas Green and Nestler, {Eric J.}",
year = "2006",
doi = "10.1016/B978-012397632-1/50015-0",
language = "English (US)",
isbn = "9780123976321",
pages = "181--193",
booktitle = "Gene Therapy of the Central Nervous System: From Bench to Bedside",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Psychiatric Applications of Viral Vectors

AU - Green, Thomas

AU - Nestler, Eric J.

PY - 2006

Y1 - 2006

N2 - This chapter compares and contrasts four viral vector systems (herpes simplex 1 virus, adeno-associated virus, sindbis virus, and lentivirus), best suited for gene transfer into the brain and describes the basic strategies where viral-mediated gene transfer has proven useful. The ideal viral vector for psychiatric research in animals, and eventually for treatments of humans, must have good neurotropism, cause little or no toxicity, and express the target protein(s) for extended periods of time. Viral vectors expressing the transcription factor, cAMP-response-element binding protein (CREB) or a dominant-negative mutant form of CREB (mCREB) affect behavior in rodent models ranging from depression to anxiety to drug dependence. The final discussion outlines novel uses and improvements to vector technology and describes current obstacles preventing viral vectors from becoming clinically viable. Obstacles to a clinically viable gene therapy include finding good targets, designing better vectors, controlling expression, and safety issues.

AB - This chapter compares and contrasts four viral vector systems (herpes simplex 1 virus, adeno-associated virus, sindbis virus, and lentivirus), best suited for gene transfer into the brain and describes the basic strategies where viral-mediated gene transfer has proven useful. The ideal viral vector for psychiatric research in animals, and eventually for treatments of humans, must have good neurotropism, cause little or no toxicity, and express the target protein(s) for extended periods of time. Viral vectors expressing the transcription factor, cAMP-response-element binding protein (CREB) or a dominant-negative mutant form of CREB (mCREB) affect behavior in rodent models ranging from depression to anxiety to drug dependence. The final discussion outlines novel uses and improvements to vector technology and describes current obstacles preventing viral vectors from becoming clinically viable. Obstacles to a clinically viable gene therapy include finding good targets, designing better vectors, controlling expression, and safety issues.

UR - http://www.scopus.com/inward/record.url?scp=84862841357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862841357&partnerID=8YFLogxK

U2 - 10.1016/B978-012397632-1/50015-0

DO - 10.1016/B978-012397632-1/50015-0

M3 - Chapter

AN - SCOPUS:84862841357

SN - 9780123976321

SP - 181

EP - 193

BT - Gene Therapy of the Central Nervous System: From Bench to Bedside

PB - Elsevier Inc.

ER -